SI1456182T1 - Pirimidinski derivati kot modulatorji insulinu podobnega receptorja rastnega faktorja-1 (IGF-I) - Google Patents

Pirimidinski derivati kot modulatorji insulinu podobnega receptorja rastnega faktorja-1 (IGF-I)

Info

Publication number
SI1456182T1
SI1456182T1 SI200230824T SI200230824T SI1456182T1 SI 1456182 T1 SI1456182 T1 SI 1456182T1 SI 200230824 T SI200230824 T SI 200230824T SI 200230824 T SI200230824 T SI 200230824T SI 1456182 T1 SI1456182 T1 SI 1456182T1
Authority
SI
Slovenia
Prior art keywords
insuline
igf
modulators
receptor
growth factor
Prior art date
Application number
SI200230824T
Other languages
English (en)
Inventor
Bernard Barlaam
Andrew Pape
Andrew Thomas
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SI1456182T1 publication Critical patent/SI1456182T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SI200230824T 2001-12-07 2002-12-03 Pirimidinski derivati kot modulatorji insulinu podobnega receptorja rastnega faktorja-1 (IGF-I) SI1456182T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0104140A SE0104140D0 (sv) 2001-12-07 2001-12-07 Novel Compounds
EP02791165A EP1456182B1 (en) 2001-12-07 2002-12-03 Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (igf-i)
PCT/SE2002/002221 WO2003048133A1 (en) 2001-12-07 2002-12-03 Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (igf-i)

Publications (1)

Publication Number Publication Date
SI1456182T1 true SI1456182T1 (sl) 2009-08-31

Family

ID=20286257

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200230824T SI1456182T1 (sl) 2001-12-07 2002-12-03 Pirimidinski derivati kot modulatorji insulinu podobnega receptorja rastnega faktorja-1 (IGF-I)

Country Status (33)

Country Link
US (3) US7521453B2 (sl)
EP (1) EP1456182B1 (sl)
JP (1) JP4347051B2 (sl)
KR (1) KR100930558B1 (sl)
CN (1) CN1289486C (sl)
AR (1) AR037736A1 (sl)
AT (1) ATE425150T1 (sl)
AU (1) AU2002365864B2 (sl)
BR (1) BR0214605A (sl)
CA (1) CA2467838C (sl)
CO (1) CO5590919A2 (sl)
CY (1) CY1109101T1 (sl)
DE (1) DE60231542D1 (sl)
DK (1) DK1456182T3 (sl)
EG (1) EG24930A (sl)
ES (1) ES2323125T3 (sl)
HK (1) HK1067631A1 (sl)
HU (1) HUP0401855A3 (sl)
IL (2) IL162376A0 (sl)
IS (1) IS7294A (sl)
MX (1) MXPA04005347A (sl)
MY (1) MY135705A (sl)
NO (1) NO327502B1 (sl)
NZ (1) NZ533130A (sl)
PL (1) PL369528A1 (sl)
PT (1) PT1456182E (sl)
RU (1) RU2317291C2 (sl)
SE (1) SE0104140D0 (sl)
SI (1) SI1456182T1 (sl)
TW (1) TWI324152B (sl)
UA (1) UA78259C2 (sl)
WO (1) WO2003048133A1 (sl)
ZA (1) ZA200404223B (sl)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA05001096A (es) 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
NZ545270A (en) 2003-07-30 2010-04-30 Rigel Pharmaceuticals Inc 2,4-Pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
JP4741491B2 (ja) * 2003-08-07 2011-08-03 ライジェル ファーマシューティカルズ， インコーポレイテッド 抗増殖剤としての２，４−ピリミジンジアミン化合物および使用
JP4916883B2 (ja) * 2003-10-15 2012-04-18 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド イミダゾピラジンチロシンキナーゼ阻害剤
KR20060123164A (ko) 2003-10-17 2006-12-01 아스트라제네카 아베 암 치료에 사용하기 위한 4-(피라졸-3-일아미노)피리미딘유도체
MY141220A (en) * 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
PT1732898E (pt) * 2004-03-12 2008-04-07 Analytecon Sa Derivados de tetrahidroisoquinolina e tetrahidrobenzazepina como inibidores igf-1r
US7973061B2 (en) * 2004-03-31 2011-07-05 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
TWI378934B (en) 2004-04-02 2012-12-11 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
DE102004022897A1 (de) * 2004-05-10 2005-12-08 Bayer Cropscience Ag Azinyl-imidazoazine
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
WO2006068770A1 (en) 2004-11-24 2006-06-29 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
EP1841760B1 (en) 2004-12-30 2011-08-10 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
BRPI0606318B8 (pt) 2005-01-19 2021-05-25 Rigel Pharmaceuticals Inc composto, composição, e, uso de um composto
ATE530545T1 (de) * 2005-02-04 2011-11-15 Astrazeneca Ab Als kinaseinhibitoren geeignete pyrazolylaminopyridinderivate
ES2308731T3 (es) 2005-02-16 2008-12-01 Astrazeneca Ab Compuestos quimicos.
GB0507347D0 (en) * 2005-04-12 2005-05-18 Astrazeneca Ab Chemical compounds
JP2008540335A (ja) * 2005-04-27 2008-11-20 アストラゼネカ・アクチエボラーグ ピラゾリル・ピリミジン誘導体の疼痛治療における使用
NZ564317A (en) * 2005-05-16 2011-01-28 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
NZ563454A (en) 2005-06-08 2011-03-31 Rigel Pharmaceuticals Inc 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US7566721B2 (en) * 2005-08-08 2009-07-28 Osi Pharmaceuticals, Inc. Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
TW200738281A (en) 2005-08-24 2007-10-16 Wyeth Corp Bazedoxifene acetate formulations
JP5055284B2 (ja) 2005-09-20 2012-10-24 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー インシュリン様成長因子−１受容体キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー
ES2391783T3 (es) * 2005-10-28 2012-11-29 Astrazeneca Ab Derivados de 4-(3-aminopirazol)pirimidina para su uso como agentes inhibidores de las tirosina cinasas en el tratamiento del cáncer
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
MX2008015657A (es) * 2006-06-09 2009-02-04 Novartis Ag Polipeptidos de factor de crecimiento similares a insulina estabilizados.
KR20090023698A (ko) * 2006-06-15 2009-03-05 베링거 인겔하임 인터내셔날 게엠베하 2-아닐리노-4-아미노알킬렌아미노피리미딘
AU2007263655A1 (en) * 2006-06-30 2008-01-03 Astrazeneca Ab Pyrimidine derivatives useful in the treatment of cancer
US8222256B2 (en) * 2006-07-05 2012-07-17 Exelixis, Inc. Methods of using IGFIR and ABL kinase modulators
WO2008129255A1 (en) * 2007-04-18 2008-10-30 Astrazeneca Ab 5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer
WO2008135786A1 (en) * 2007-05-04 2008-11-13 Astrazeneca Ab Amino-thiazolyl- pyrimidine derivatives and their use for the treatment of cancer
UA99459C2 (en) * 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
US8178091B2 (en) 2007-05-21 2012-05-15 University Of Washington Compositions and methods for the treatment of respiratory disorders
WO2009019518A1 (en) * 2007-08-09 2009-02-12 Astrazeneca Ab Pyrimidine compounds having a fgfr inhibitory effect
JP2011510018A (ja) * 2008-01-18 2011-03-31 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 癌治療のためのイミダゾピラジノール誘導体
JP2011520970A (ja) * 2008-05-19 2011-07-21 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換されたイミダゾピラジン類およびイミダゾトリアジン類
UY31885A (es) * 2008-06-11 2010-01-29 Astrazeneca Ab Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
DE102008041214A1 (de) 2008-08-13 2010-02-18 Bayer Cropscience Ag N-substituierte Azinylakyl-azincarboxamide und deren Analoge
RU2011116928A (ru) * 2008-09-30 2012-11-20 Астразенека Аб (Se) Гетероциклические ингибиторы jак киназы
EP2400985A2 (en) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
JP2012519170A (ja) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519281A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012524119A (ja) 2009-04-20 2012-10-11 オーエスアイ・ファーマシューティカルズ，エルエルシー Ｃ−ピラジン−メチルアミンの調製
JP2012526138A (ja) * 2009-05-07 2012-10-25 オーエスアイ・ファーマシューティカルズ，エルエルシー 副腎皮質癌を治療するためのｏｓｉ−９０６の使用
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
WO2011109584A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2519826A2 (en) 2010-03-03 2012-11-07 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2544672A1 (en) 2010-03-09 2013-01-16 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
BR112012023551A2 (pt) 2010-03-18 2015-09-15 Bayer Ip Gmbh aril e hetaril sulfonamidas como agentes ativos contra estresse abiótico em plantas
WO2011144742A1 (en) 2010-05-21 2011-11-24 Chemilia Ab Novel pyrimidine derivatives
US8546443B2 (en) * 2010-12-21 2013-10-01 Boehringer Ingelheim International Gmbh Benzylic oxindole pyrimidines
AU2012212075A1 (en) 2011-02-02 2013-07-18 Amgen Inc. Methods and compositons relating to inhibition of IGF-1R
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
DK2688883T3 (en) 2011-03-24 2016-09-05 Noviga Res Ab pyrimidine
US9096691B2 (en) 2011-04-13 2015-08-04 Eastman Chemical Company Cellulose ester optical films
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
WO2013071056A2 (en) 2011-11-11 2013-05-16 Duke University Combination drug therapy for the treatment of solid tumors
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
EP2961412A4 (en) 2013-02-26 2016-11-09 Triact Therapeutics Inc CANCER THERAPY
CA2923667A1 (en) 2013-09-09 2015-03-12 Triact Therapeutics, Inc. Cancer therapy
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
CN115124475B (zh) * 2022-07-11 2023-11-10 贵阳学院 一种嘧啶衍生物及其制备方法和用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1417402A (en) * 1972-03-30 1975-12-10 Boots Co Ltd Pharmacologically active anilinobenzothiazoles
DE2426180A1 (de) 1974-05-29 1975-12-18 Bayer Ag Verfahren zum faerben von polyurethankunststoffen
US4485284A (en) * 1982-01-11 1984-11-27 Advanced Moisture Technology, Inc. Apparatus and process for microwave moisture analysis
HU206337B (en) 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CA2104053C (en) * 1992-08-31 1999-04-13 Miguel A. Cacho Automated fluid bed process
US5935966A (en) 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
JPH11512390A (ja) 1995-09-01 1999-10-26 シグナル ファーマシューティカルズ，インコーポレイテッド ピリミジンカルボキシレートおよび関連化合物ならびに炎症状態を処置するための方法
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
JP2001517146A (ja) * 1997-03-27 2001-10-02 グラツト ゲゼルシヤフト ミツト ベシユレンクテル ハフツング 生産物の湿度を測定することにより、渦流流体層又は可動注入体内の顆粒化−、塊状化−、インスタント製品化−、コーティング−及び乾燥プロセス加工の監視及び／又は制御及び調整方法、並びに、前記方法を実施するためのエアエンジニアリング装置
US6247246B1 (en) * 1998-05-27 2001-06-19 Denver Instrument Company Microwave moisture analyzer: apparatus and method
ES2274634T3 (es) 1998-08-29 2007-05-16 Astrazeneca Ab Compuestos de pirimidina.
HU230394B1 (hu) 1998-11-10 2016-04-28 Janssen Pharmaceutica N.V. HIV-vírus szaporodását gátló pirimidin-származékok
WO2000035455A1 (en) 1998-12-15 2000-06-22 Telik, Inc. Heteroaryl-aryl ureas as igf-1 receptor antagonists
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
DE19917785A1 (de) * 1999-04-20 2000-10-26 Bayer Ag 2,4-Diamino-pyrimidin-Derivate
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
KR100785360B1 (ko) 1999-09-24 2007-12-18 얀센 파마슈티카 엔.브이. 항바이러스 조성물
US6455525B1 (en) * 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
AU2001237041B9 (en) 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
DK1282607T3 (en) * 2000-05-08 2016-02-01 Janssen Pharmaceutica Nv Prodrugs of HIV replication inhibiting pyrimidines
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP4105949B2 (ja) * 2000-09-15 2008-06-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) * 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
PT1355905E (pt) * 2000-12-21 2007-05-31 Vertex Pharma Compostos de pirazole úteis como inibidores de proteínaquinase
EP1423380B1 (en) * 2001-08-03 2010-12-15 Vertex Pharmaceuticals Incorporated Pyrazole-derived kinase inhibitors and uses thereof
DE60226154T2 (de) * 2001-08-03 2009-05-20 Vertex Pharmaceuticals Inc., Cambridge Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
US6747461B2 (en) * 2001-10-25 2004-06-08 Pioneer Hi-Bred International, Inc. Apparatus and method for monitoring drying of an agricultural porous medium such as grain or seed
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
MY141220A (en) * 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
PT1812440E (pt) * 2004-11-04 2011-01-25 Vertex Pharma Pirazolo[1,5-a]pirimidinas úteis enquanto inibidores de proteínas cinases
ES2308731T3 (es) * 2005-02-16 2008-12-01 Astrazeneca Ab Compuestos quimicos.
WO2007056164A2 (en) * 2005-11-03 2007-05-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
AU2007263655A1 (en) * 2006-06-30 2008-01-03 Astrazeneca Ab Pyrimidine derivatives useful in the treatment of cancer
TW200823196A (en) * 2006-11-01 2008-06-01 Astrazeneca Ab New use
TW200826937A (en) * 2006-11-01 2008-07-01 Astrazeneca Ab New use

Also Published As

Publication number Publication date
TW200409634A (en) 2004-06-16
CN1289486C (zh) 2006-12-13
DK1456182T3 (da) 2009-06-29
KR100930558B1 (ko) 2009-12-09
MXPA04005347A (es) 2004-09-27
NO327502B1 (no) 2009-07-27
DE60231542D1 (de) 2009-04-23
NZ533130A (en) 2006-11-30
KR20050044698A (ko) 2005-05-12
PL369528A1 (en) 2005-05-02
HK1067631A1 (en) 2005-04-15
RU2004121029A (ru) 2006-01-10
WO2003048133A1 (en) 2003-06-12
MY135705A (en) 2008-06-30
US7521453B2 (en) 2009-04-21
ZA200404223B (en) 2005-08-29
BR0214605A (pt) 2004-09-14
PT1456182E (pt) 2009-05-26
US20120095011A1 (en) 2012-04-19
HUP0401855A3 (en) 2008-06-30
IL162376A (en) 2011-07-31
CY1109101T1 (el) 2014-07-02
RU2317291C2 (ru) 2008-02-20
IL162376A0 (en) 2005-11-20
US20090131463A1 (en) 2009-05-21
CA2467838C (en) 2010-10-12
AU2002365864B2 (en) 2007-08-30
EP1456182B1 (en) 2009-03-11
IS7294A (is) 2004-06-03
TWI324152B (en) 2010-05-01
AR037736A1 (es) 2004-12-01
EP1456182A1 (en) 2004-09-15
CN1617858A (zh) 2005-05-18
CA2467838A1 (en) 2003-06-12
JP4347051B2 (ja) 2009-10-21
CO5590919A2 (es) 2005-12-30
AU2002365864A1 (en) 2003-06-17
EG24930A (en) 2011-01-11
JP2005515998A (ja) 2005-06-02
UA78259C2 (en) 2007-03-15
SE0104140D0 (sv) 2001-12-07
HUP0401855A2 (hu) 2004-12-28
US20050054638A1 (en) 2005-03-10
NO20042872L (no) 2004-07-06
ATE425150T1 (de) 2009-03-15
ES2323125T3 (es) 2009-07-07

Similar Documents

Publication Publication Date Title
EG24930A (en) Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (IGF-I)
PL375882A1 (en) Heterocyclic aromatic compounds useful as growth hormone secretagogues
HK1064384A1 (en) Preparation of aminopyrimidine compounds
HK1135382A1 (en) Substituted pyridinones as modulators of p38 map kinase
IL162189A0 (en) Pyrimidine compounds
HUP0500733A3 (en) Crystallization of igf-1
AU2003269885A1 (en) Antisense modulation of g protein-coupled receptor kinase 6 expression
AU2002359574A1 (en) Antisense modulation of g protein-coupled receptor etbr-lp-2 expression
AU2002230164A1 (en) Crystal of pyrimidine nucleoside derivative
AU2002359160A1 (en) PIPAZOLO (1,5-a) PYRIMIDINE DERIVATIVES AS MODULATORS OF PPAR
AU2002314182A1 (en) Cortistatin analogs capable of binding selectively to growth hormone secretagogue receptors
GB0112803D0 (en) Pyrimidine derivatives
GB0119477D0 (en) Pyrimidine derivatives
GB0111083D0 (en) Formation of small crystals
GB0127380D0 (en) Formation of small crystals
AU2003201079A1 (en) Improved communication of tv-anytime crids
GB0119475D0 (en) Pyrimidine derivatives
GB0112807D0 (en) Pyrimidine derivatives
GB0112808D0 (en) Pyrimidine derivatives
GB0112809D0 (en) Pyrimidine derivatives
AU2002247732A1 (en) Substituted pyrimidinone derivatives as ligands of integrin receptors
GB0129479D0 (en) Correction of data for imaging
AU2002251664A1 (en) Use of npy y2 receptor antagonists